LQDA
Liquidia Corporation
1W: -0.1%
1M: +9.1%
3M: +2.3%
YTD: +16.6%
1Y: +133.8%
3Y: +415.6%
5Y: +1221.7%
$36.61
+1.41 (+4.01%)
After Hours: $33.05 (-3.55, -9.71%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$3.2B
52W Range11.26-46.67
Volume1,016,532
Avg Volume1,890,952
Beta0.56
Dividend—
Analyst Ratings
Company Info
CEORoger A. Jeffs
Employees170
SectorHealthcare
IndustryBiotechnology
IPO Date2018-07-26
Websiteliquidia.com
419 Davis Drive
Morrisville, NC 27560
US
Morrisville, NC 27560
US
919 328 4400
About Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Latest News
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B
Liquidia Stock Up 135% as Insider Sells $1.3 Million in Shares
FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma
GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer
Novartis Strikes $3B Oncology Deal for Breast Cancer Asset
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Moomaw Scott | S-Sale | 1,314 | $36.48 | 2026-03-23 |
| Moomaw Scott | M-Exempt | 17,000 | $3.40 | 2026-03-23 |
| Moomaw Scott | S-Sale | 17,000 | $36.81 | 2026-03-23 |
| Moomaw Scott | M-Exempt | 17,000 | $3.40 | 2026-03-23 |
| Saggar Rajeev | S-Sale | 35,365 | $36.30 | 2026-03-13 |